AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01405300 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 34.8 g dextrose, 150 g heavy whipping cream, 39g chocolate syrup, 15 g sunflower oil, 22 g safflower oil, 27 g powdered egg whites, 9.6 g of fiber supplement, water and crushed ice. It will deliver \~1200 kcal.
Study NCT01405300 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peanut
Description: 34.8 g dextrose. 137 g heavy whipping cream, 39g chocolate syrup + 3 oz peanuts with skin. It will deliver \~1200 kcal.
Study NCT03650088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss with digital tools
Description: Participants will monitor their diet in a study smart phone app using a 'traffic light' approach where foods are categorized as red (high fat and/or calorie), yellow (moderate fat/calorie, high nutrient), or green (low fat/calorie, high nutrient) and adhere to a red food limit recommendation, weigh daily on a digital scale whose data syncs to the study app, gradually increase physical activity and track it using a wearable device for which data is also synced to the app, and monitor blood glucose using Continuous Glucose Monitoring. Participants will meet weekly with a trained interventionist for behavioral lessons (adapted from Diabetes Prevention Program curriculum) and counseling.
Study NCT01022658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: For diabetes treatment: metformin continued with insulin (according to arms)
Study NCT03945461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: xylitol based, peppermint flavored gum
Study NCT00100789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 3,000 mg/m2 IV over 30 minutes on days 1 and 15 (q28 days).
Study NCT00100789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 150 mg/m2 IV over 1 hour on days 1 and 15 (q 28 day cycle), administered after gemcitabine
Study NCT01725217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: 1 vaccination at visit 1, conjugate vaccine, Intramuscular (IM) injection
Study NCT03472950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine 500 MG
Description: Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
Study NCT03472950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine 1000 MG
Description: Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
Study NCT00064987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Testicular biopsy
Description: Outpatient surgical procedure.
Study NCT00064987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Testicular biopsy
Description: Outpatient surgical procedure.
Study NCT00064987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gonadotropin releasing hormone (GnRH)
Description: Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
Study NCT00064987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gonadotropin releasing hormone (GnRH)
Description: Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
Study NCT00064987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: follicle stimulating hormone (FSH)
Description: 75 IU subcutaneous injection daily for four months.
Study NCT03495375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment with a probiotic
Description: All participants will take the probiotic once daily for 10 weeks in the form of a powder that can be spread on top of cold foods such as muesli, salad, or yogurt.
Study NCT03495375 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment with placebo
Description: All participants will take the placebo once daily for 10 weeks.
Study NCT03948646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofpironium Bromide, 15%
Description: Active
Study NCT04185675 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The laryngoscope used for tracheal intubation under general anesthesia for patients with expected non-difficult airway conditions.
Description: All the patients will receive the same anesthesia induction, and are randomized to three groups to receive different types of laryngoscope for intubation. These are the direct Macintosh laryngoscope, adjustable videolaryngoscope and nonadjustable videolaryngoscope.
Study NCT04185675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The laryngoscope used for tracheal intubation under general anesthesia for patients with expected non-difficult airway conditions.
Description: All the patients will receive the same anesthesia induction, and are randomized to three groups to receive different types of laryngoscope for intubation. These are the direct Macintosh laryngoscope, adjustable videolaryngoscope and nonadjustable videolaryngoscope.
Study NCT00307905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traumeel S
Description: homeopathic remedy
Study NCT00307905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo remedy
Description: identical size, shape and taste of treatment medication
Study NCT02506192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified-Release Prednisone
Description: Modified-Release Prednisone oral tablets (2x5mg) daily for 8 weeks
Study NCT02506192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablets (2x5mg) daily for 8 weeks
Study NCT03070535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIGH and LOW meal ingestion
Description: The study will examine CSF biomarker responses to HIGH and LOW meals in 80 men and women with and without the E4 allele in a cross-over design. After an overnight fast, participants will ingest either a HIGH or LOW meal on separate days 3-5 weeks apart in random order. Three hours after meal ingestion, participants will undergo a cognitive battery, followed by spinal fluid collection. Blood samples will also be taken at 7 time points before and after meal ingestion.
Study NCT03029910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy and eccentric exercise
Description: 12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. Previously subjects should cool their leg in ice water during sixteen minutes at a temperature of 8ºC (+/-2ºC)
Study NCT03029910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration and eccentric exercise
Description: 12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. During the exercise subjects will be subjected to vibration. Vibration parameters: Frequency: 35Hz, Amplitude: 4 millimeters, Force: 3,9G
Study NCT02938208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jupiter Full Face Mask
Description: Full Face Mask for the treatment of obstructive sleep apnea (OSA) using CPAP therapy.
Study NCT01588561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Nicotine
Description: Subjects received a single infusion of nicotine, 1.5 mg/70kg (New England Compounding Center, Framingham, MA), administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
Study NCT01588561 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline - placebo
Description: Subjects received a single infusion of saline, administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
Study NCT03337971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: A food-grade proprietary product containing corn starch in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland
Study NCT03337971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MBPM
Description: A food-grade proprietary product containing per 100g; milk protein (46.4%), carbohydrate (40.6%), fat (0.7%), Vitamin D (2ug); calcium (1840mg) in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland
Study NCT02068625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: Rasagiline 1mg daily orally for 7 days
Study NCT02068625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral treatment with placebo for 7 days
Study NCT01435213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atipamezole
Description: Administration of a single dose of 5-150 micrograms of atipamezole as an intravenous infusion
Study NCT01435213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: A single dose of 1.2 mg/kg of atomoxetine administered orally
Study NCT01435213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A single dose of ketamine (approximately 60 mg) administered as an intravenous infusion
Study NCT01435213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Description: 30-45 min cold pressor test of the foot
Study NCT01435213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin administered as an intravenous infusion to induce hypoglycemia
Study NCT01435213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single dose of placebo (capsules) administered orally
Study NCT03513276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100cc of 2% ropivacaine
Description: Multimodal analgesia + Local infiltration anesthesia
Study NCT03513276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution
Description: Multimodal analgesia + Saline solution
Study NCT03513276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline 10mcg/ml
Study NCT01327677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 25-50 mcg every 20 minutes
Study NCT01327677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 20mcg/demand dose with an 8 minute lock out
Study NCT01693536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counselling
Description: as in Arm Description
Study NCT03038295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Oral propranolol:0.25mg/kg daily(every 24 hours)；Eye drop propranolol(0.2%):3 microdrops,in each eye, four times daily (every 6 hours) .Both administration routes will be discontinued until retinal vascularization will be completed, but no more than 90 days.The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:Atropine.Isoproterenol hydrochloride (isoprenaline).Terlipressin.Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular).
Study NCT03038295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral/eye drop placebo will be taken in enrolled newborns. Other treatment will follow the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group.
Study NCT04208555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boric Acid Vaginal Suppository
Description: Boric acid vaginal suppository (600 mg/day) for 14 days
Study NCT04208555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terconazole Vaginal Suppository
Description: Terconazole 80 mg vaginal suppository daily for 6 days
Study NCT03948646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle gel
Study NCT05893524 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Timed Up-and-Go (TUG single-task)
Description: The TUG test is a well-established clinical test of one mobility sequence: rising from an armchair, walking straight ahead, passing a line marked on the floor, turning around, walking back, and sitting down again.
Study NCT05893524 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Timed Up-and-Go dual-task (TUGdt)
Description: Two dual-task tests including TUG (TUGdt) were carried out: TUGdt naming animals and TUGdt months backwards. The outcomes registered were: time scores for TUG single-task and both TUGdt tests, TUGdt costs (relative time difference between TUG single-task and TUGdt), number of different animals named, number of months recited in correct order, number of animals per 10 s, and number of months per 10 s.
Study NCT05893524 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical functional assessment
Description: The diagnostic procedure was part of the clinical routine for patients undergoing memory assessment and involved a geriatrician's careful evaluation of the patient's history and cognitive testing including Mini-Mental State Examination (MMSE), Clock Drawing Test, Verbal Fluency Test, and Trail Making Test A and B. In addition, all participants carried out short versions of the Geriatric Depression Scale and the General Motor Function Assessment Scale, as well as static balance according to the Bohannon Method, and hand grip strength using a dynamometer.
Study NCT01736982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants earn reinforcement in the form of prizes for breath samples that test negative for cigarette smoking.
Study NCT01736982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard smoking cessation counseling
Study NCT01736982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard smoking cessation counseling
Study NCT01736982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: transdermal nicotine replacement \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\]
Study NCT01736982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: transdermal nicotine replacement \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\]
Study NCT01736982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Breath sample monitoring
Study NCT01957514 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo tissue biopsy, blood, buccal mucosa, saliva, and urine collection
Study NCT01957514 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01957514 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01957514 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03052751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB7665
Description: UCB7665 will be administered in 2 different dosages (dose 1 and dose 2). UCB7665 (INN: Rozanolixizumab) is a humanized monoclonal antibody that is being developed for treatment of IgG autoantibody-mediated conditions such as myasthenia gravis (MG)
Study NCT00983281 — intervention group
Intervention type: DRUG
Intervention: Hextend
Description: IV fluid resuscitation to restore euvolemia after traumatic injury and surgery.
Study NCT02041130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Study NCT00301405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Open label drug
Study NCT00183716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Recovery and Empowerment Model (TREM)
Description: TREM is a 29-session group intervention for women who have experienced psychological trauma (e.g., childhood physical or sexual abuse), focusing on skill development, understanding the effects of trauma, and empowerment.
Study NCT00183716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Participants will receive usual care for women who have experienced psychological trauma.
Study NCT00183716 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive usual care for women who have experienced psychological trauma.
Study NCT02239250 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water filter and cookstove
Description: The Vestergaard Frandsen Lifestraw Family™ 2.1 is a point-of-use water treatment system.Water is poured through a 20 micron pre-filter into a 6L influent water tank.This water then filters through a 0.20 micron hollow-fiber ultrafiltration membrane into a 5.5L storage container.Water is then poured through a plastic tap, which prevents re-contamination.This system filters up to 18,000L of water.The system exceeds the WHO's highly protective standard for household water treatment technologies.The EcoZoom™ Spartan stove concentrates the combustion process while channeling airflow to completely burn the fuel provided.The stove has a ceramic combustion chamber within a steel housing, which is topped with a cast iron stove.The stove includes a rack for placing firewood and a pot skirt that improves the thermal efficiency.The cookstoves and filters will be delivered together at no cost to participating households.Households will receive instructions on how to operate these devices.
Study NCT04152447 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VR device
Description: Patients use a VR device
Study NCT01736982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Breath sample monitoring
Study NCT04111666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AL101
Description: Active dose of AL101
Study NCT04111666 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution administered as a single and multiple infusion as placebo.
Study NCT01995604 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Application of Sterile 0.9% Saline Solution
Description: Application of Sterile 0.9% Saline Solution to half of face after UltraPulse laser therapy.
Study NCT01995604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of dHACM
Description: Application of dHACM to half of face after UltraPulse laser therapy.
Study NCT00683462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00683462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: Capsules 5 mg/day (once a day) for 2 weeks
Study NCT00683462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: Capsules 50 mg/day (once a day) for 2 weeks
Study NCT00924313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (C-11 Acetate)
Description: 11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
Study NCT02583594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02583594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02583594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alemtuzumab GZ402673
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous
Study NCT02583594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alemtuzumab GZ402673
Description: Pharmaceutical form:injection Route of administration: subcutaneous
Study NCT02583594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02583594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02583594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceterizine
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02583594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02772341 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Salt room with halogenerator
Description: Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room with salt aerosol produced by a halogenerator (study group) or halotherapy without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values. The halogenerator is located outside the salt room.